Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer
DOI:
https://doi.org/10.54097/pjjvd009Keywords:
TNBC, ICI, PD-1/PD-L1.Abstract
Triple negative breast cancer (TNBC) is still the most serious subtype of breast cancer because of the least favorable prognosis due to the greatest recurrence and mortality rates. In the past decade, with an deeper understanding of tumor biology, it became possible to identify subgroups of patients with molecular characteristics and apply numerous novel targeted therapies. In this aspect, immune checkpoint inhibitors (ICIs) have developed as a promising therapy method for TNBC patients to improve pathologic complete response rate and the outcomes of patients. Nowadays, PD-1/PD-L1 inhibitors are used in the clinic applying for TNBC alone or with other types of therapies. Despite the advances, there are many challenges including optimizing patient selection, reducing resistance and enhancing control of immune-related adverse events. This review includes an overview of current clinical treatment for TNBC and pathways of PD-L1. The ongoing clinical trials, current challenges, and future perspectives about ICI, particularly anti-PD-1/PD-L1 therapy, are briefly discussed to portray their promising prospects.
Downloads
References
Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022 Aug 29; 15 (1): 121.
Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019 Oct 1; 30 (10): 1541-1557.
Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020 Dec; 31 (12): 1623-1649.
Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021 Sep 11; 398 (10304): 1002-1014.
Vranic S, Cyprian FS, Gatalica Z, Palazzo J. PD-L1 status in breast cancer: Current view and perspectives. Semin Cancer Biol. 2021 Jul; 72: 146-154.
Qin G, Wang X, Ye S, et al. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer. Nat Commun. 2020 Apr 3; 11 (1): 1669.
Zhang J, Zhang G, Zhang W, et al. Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer. Cell Death Differ. 2022 Nov; 29 (11): 2247-2261.
Kong T, Ahn R, Yang K, et al. CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers. Cancer Res. 2020 Feb 1; 80 (3): 444-457.
Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. BMJ. 2023 May 30; 381: e071674.
ClinicalTrials.gov https://www.clinicaltrials.gov/search?cond=Triple%20Negative%20Breast%20Cancer&intr=PD-L1%EF%BC%8CPD-1.
Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022 Aug 29; 15 (1): 121.
Sharma P, Siddiqui BA, Anandhan S, et al. The Next Decade of Immune Checkpoint Therapy. Cancer Discov. 2021 Apr; 11 (4): 838-857.
Nguyen BL, Phung CD, Pham DV, et al. Liposomal co-delivery of toll-like receptors 3 and 7 agonists induce a hot triple-negative breast cancer immune environment. J Control Release. 2023 Aug 12; 361: 443-454.
Patterson-Fortin J, Jadhav H, Pantelidou C, et al. Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer. Nat Commun. 2023 Mar 13; 14 (1): 1390.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
